Laura Clague, Chief Financial Officer at Travere Therapeutics, Inc. (TVTX), sold 1,238 shares at $27.40 ($34K) on 2022-01-31, disclosed to the SEC on 2022-02-02.
Scheduled sale ($34k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| TVTX | SELL | 2022-01-26 | $103K | — | Filing → |
| TVTX | SELL | 2022-01-12 | $206K | — | Filing → |
| TVTX | SELL | 2021-08-17 | $24K | — | Filing → |